Sudeep Pharma logo

Sudeep Pharma financials and balance sheet

NSE: SUDEEPPHRMBSE: 544619Chemicals & PetrochemicalsSmall Cap

Last close ₹966.20up ₹4.20 (0.44%)BSE ₹964.15

Share price at the NSE close on 23 Oct 2026. Previous close ₹962.00.

Range of traded prices from listing on 28 Nov 2025 to 23 Oct 2026
₹524.05Low, 21 Jan 2026₹1,378.00High, 7 Sep 2026
Market cap
₹10,913 Cr654th largest listed
P/E
59.7
P/B
12.4
Dividend yield
0.16%
ROE
20.7%
ROCE
20.8%
Debt to equity
0.17
Volume, NSE
3,80,83351.0% delivered

1 year at a glance

Consolidated: the company and its subsidiaries together. ₹ crore, years to March.Sudeep Pharma annual reports

Revenue, net profit and borrowings, ₹ crore

  • Revenue
  • Net profit
  • Borrowings

Operating and net margin, per cent

  • Operating margin
  • Net margin

Results for the year to Mar 2026

Consolidated: the company and its subsidiaries together. ₹ crore.

From revenue to net profit

  1. Revenue642
  2. Materials and goods−227
  3. Employee costs−52
  4. Other expenses−141
  5. Operating profit222
  6. Depreciation−15
  7. Other income+29
  8. One-off items0.0
  9. Finance costs−7.6
  10. Profit before tax228
  11. Tax−54
  12. Net profit174

What the company owns

  • Plant, investments and other assets₹617 Cr
  • Receivables₹228 Cr
  • Inventory₹216 Cr
  • Cash and bank₹115 Cr

What pays for it: net worth and liabilities

  • Net worth₹898 Cr
  • Borrowings₹148 Cr
  • Owed to suppliers₹68 Cr
  • Other liabilities₹60 Cr

Sudeep Pharma business segments, year to Mar 2026

A reportable segment is a line of business the company must report on its own. Consolidated, ₹ crore, as the company reports them.Sudeep Pharma segment results by quarter

Revenue by segment

₹642 CrTotal
  • Pharmaceutical, food and nutrition₹363 Cr56.5% of total
  • Speciality Ingredients₹280 Cr43.5% of total

Profit by segment

  • Pharmaceutical, food and nutrition₹114 Cr54.8% of total
  • Speciality Ingredients₹94 Cr45.2% of total

Segment results by year

Consolidated, ₹ crore, years to March.

  • Pharmaceutical, food and nutrition

    Revenue, ₹ crore
    Profit, ₹ crore
  • Speciality Ingredients

    Revenue, ₹ crore
    Profit, ₹ crore
₹ croreMar 2026
Revenue of all businesses642
Company revenue, as in its results642
Revenue363
Profit114
Margin31.3%
Return on capital22.3%
Assets727
Liabilities218
Capital employed509
Revenue280
Revenue8
Profit is before tax and finance costs, the way companies report their segments.

Profit and loss

Consolidated, ₹ crore, years to March.Sudeep Pharma quarterly results

₹ croreMar 2026Filed 25 Jun
Revenue from operations642
420
Materials and goods bought227
Employee costs52
Other expenses141
Operating profit before depreciation222
Operating margin34.6%
Materials, % of revenue35.4%
Employee costs, % of revenue8.1%
Other expenses, % of revenue22.0%
Depreciation and amortisation15
Operating profit after depreciation207
Other income29
Finance costs8
One-off items0
Profit before tax228
54
174
Other comprehensive income−1
Total comprehensive income173
Net margin27.1%

Balance sheet

Consolidated, ₹ crore, at 31 March.

₹ croreMar 2026Filed 25 Jun
898
883
Share capital11
Reserves872
Belonging to outside owners of subsidiaries15
148
202
75
Total assets1,175
551
624
Net debt34
Borrowings are counted again inside the liabilities due within a year and after a year.

Cash flow

Consolidated, ₹ crore, years to March.

₹ croreMar 2026Filed 25 Jun
70
126
−106
Receivables−16
Inventories−80
Payables−2
Other working capital−8
Tax paid−55
Capital spending118
Free cash flow−49
−327
247
Dividends paid0
Shares bought back0
Shares issued255
Net change in cash−10
Capital spending is part of cash from investing, and dividends paid, shares bought back and shares issued are part of cash from financing. Each is shown as an amount on a line of its own, and the section's other items are in its total only.

Per share

Consolidated, ₹ per share, years to March.Sudeep Pharma dividend history

₹ per shareMar 2026Filed 25 Jun
Earnings per share₹15.50
Diluted earnings per share₹15.50
Dividend per share₹1.50
Book value per share₹78.21
Dividend payout9.8%
Shareholder yield−3.8%
Market cap at the year end (₹ crore)6,693

Ratios

Consolidated, years to March.Sudeep Pharma PE ratio and valuation

RatioMar 2026Filed 25 Jun
Return on equity19.6%
Return on capital employed19.8%
Cash conversion39.9%
Interest cover27.2
Debt to equity0.17
Receivable days129
Inventory days347
Payable days110
Cash conversion cycle, days366
Working capital days239
Asset turnover0.55
Assets per rupee of net worth1.33
Sales per rupee of plant2.87
Capital spending to depreciation7.98
Plant being built, % of plant in use79.7%

Growth and returns over 3, 5 and 10 years

Consolidated: the company and its subsidiaries together. Each window ends with the year to Mar 2026.

Return on assets, latest year
14.7%
Cash from operations against operating profit
31.3%

Where the cash came from and went

Consolidated: the company and its subsidiaries together. ₹ crore, added up over each window, which ends with the year to Mar 2026.

₹ croreLatest year
Cash from operations70
Cash from investing−327
Cash from financing247
Capital spending118
Dividends paid0
Shares bought back0
Shares issued for cash255
Borrowings raised22
Borrowings repaid10

Accounting checks

Consolidated, years to March. Published tests of whether reported profit is backed by cash and the balance sheet.

CheckMar 2026
Altman Z-scorePublished threshold 1.8117.19
Effective tax ratePublished threshold 17.16 per cent23.58
Tax charged less tax paid, % of profitOur threshold 10 percentage points−0.74
A threshold marked as ours has no published figure; it is the line we read the check against.